# in HIV/AIDS Program. The annual

burden estimates for this activity are shown below:

Form	Responses per respond- ent	Estimated No. of respondents (× 10 sites)	Hours per re- sponse	Total hours
Session Report Form Participant Feedback Form (General Education) Neuropsychiatric Participant Feedback Form Non Physician Neuropsychiatric Participant Feedback Form Adherence Participant Feedback Form Ethics Participant Feedback Form	1 1 1 1 1 1	$\begin{array}{c} 60 \times 10 = 600 \\ 500 \times 10 = 5000 \\ 160 \times 10 = 1600 \\ 240 \times 10 = 2400 \\ 100 \times 10 = 1000 \\ 200 \times 10 = 2000 \end{array}$	0.080 0.167 0.167 0.167 0.167 0.167	48 835 267 401 167 125
Total		12,600		1,843

Written comments and recommendations concerning the proposed information collection should be sent by September 3, 2004, to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC. 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202–395– 6974.

Dated: July 29, 2004.

#### Anna Marsh,

*Executive Officer, SAMHSA.* [FR Doc. 04–17752 Filed 8–3–04; 8:45 am] BILLING CODE 4162–20–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

# Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) published in the Federal Register on April 11, 1988 (53 FR 11970), and revised in the Federal Register on June 9, 1994 (59 FR 29908) and on September 30, 1997 (62 FR 51118). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory

will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from HHS' National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at *http://workplace.samhsa.gov* and *http://www.drugfreeworkplace.gov*.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2, Room 815, Rockville, Maryland 20857; 301–443–6014 (voice), 301–443–3031 (fax).

**SUPPLEMENTARY INFORMATION:** The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100– 71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards that laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification, a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines, the following laboratories meet the minimum standards set forth in the Mandatory Guidelines:

- ACL Laboratories 8901 W. Lincoln Ave. West Allis, WI 53227, 414–328–7840 / 800–877–7016 (Formerly: Bayshore Clinical Laboratory)
- ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264
- Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770 / 888–290– 1150
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615– 255–2400
- Baptist Medical Center-Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783 (Formerly: Forensic Toxicology
- Laboratory Baptist Medical Center) Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800– 445–6917
- Diagnostic Services Inc., dba DSI, 12700 Westlinks Dr., Fort Myers, FL 33913, 239–561–8200 / 800–735–5416
- Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281
- DrugProof, Division of Dynacare/ Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2661 / 800–898–0180 (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215–674–9310
- Dynacare Kasper Medical Laboratories \*, 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, 780–451– 3702/800–661–9876
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 662–236– 2609
- Express Analytical Labs, 3405 7th Ave., Suite 106, Marion, IA 52302, 319– 377–0500
- Gamma-Dynacare Medical Laboratories \*, A Division of the Gamma-Dynacare Laboratory

Partnership, 245 Pall Mall St., London, ONT, Canada N6A 1P4, 519– 679–1630

- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608– 267–6225
- Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504– 361–8989 / 800–433–3823 (Formerly: Laboratory Specialists, Inc.)
- LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927 / 800–873–8845 (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America Holdings, 7207 N. Gessner Rd., Houston, TX 77040, 713–856–8288 / 800–800–2387
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400 / 800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Corporation of America Holdings, 1904 Alexander Dr., Research Triangle Park, NC 27709, 919–572–6900 / 800–833–3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc., CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
- Laboratory Corporation of America Holdings, 10788 Roselle St., San Diego, CA 92121, 800–882–7272 (Formerly: Poisonlab, Inc.)
- Laboratory Corporation of America Holdings, 1120 Stateline Rd. West, Southaven, MS 38671, 866–827–8042 / 800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715– 389–3734 / 800–331–3734
- MAXXAM Analytics Inc.\*, 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905–890–2555 (Formerly: NOVAMANN (Ontario) Inc.)
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651–636–7466 / 800–832–3244
- MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295 / 800–950–5295
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Dr., Minneapolis, MN 55417, 612–725– 2088
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250 / 800–350–3515

- Northwest Drug Testing, a division of NWT Inc., 1141 E. 3900 S., Salt Lake City, UT 84124, 801–293–2300 / 800– 322–3361 (Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.)
- One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 541–687–2134
- Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory)
- Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991 / 800–541–7897x7
- PharmChem Laboratories, Inc., 4600 N. Beach, Haltom City, TX 76137, 817– 605–5300 (Formerly: PharmChem Laboratories, Inc., Texas Division; Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–339–0372 / 800–821–3627
- Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590 / 800–729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800– 824–6152 (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733– 7866 / 800–433–2750 (Formerly: Associated Pathologists Laboratories, Inc.)
- Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, 610–631–4600 / 877–642–2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800–669–6995 / 847–885–2010 (Formerly: SmithKline Beecham Clinical Laboratories; International Toxicology Laboratories)
- Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 818–989–2520 / 800–877–2520 (Formerly: SmithKline Beecham Clinical Laboratories)

- Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130
- Sciteck Clinical Laboratories, Inc., 317 Rutledge Rd., Fletcher, NC 28732, 828–650–0409
- S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505– 727–6300 / 800–999–5227
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x276
- Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602– 438–8507 / 800–279–0027
- Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–377–0520 (Formerly: St. Lawrence Hospital & Healthcare System)
- St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272– 7052
- Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273
- Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305–593–2260
- US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755– 5235, 301–677–7085

\* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS' NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (**Federal Register**, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the **Federal Register** on June 9, 1994 (59 FR 29908) and on September 30, 1997 (62 FR 51118). After receiving DOT certification, the laboratory will be included in the monthly list of HHS certified laboratories and participate in the NLCP certification maintenance program.

#### Anna Marsh,

Executive Officer, SAMHSA. [FR Doc. 04–17862 Filed 8–3–04; 8:45 am] BILLING CODE 4160-20-P

# DEPARTMENT OF HOMELAND SECURITY

# Coast Guard

[USCG-2004-18761]

# Chemical Transportation Advisory Committee

**AGENCY:** Coast Guard, DHS. **ACTION:** Notice of open teleconference meeting.

SUMMARY: This notice announces a teleconference meeting of the Subcommittee of the Chemical Transportation Advisory Committee (CTAC) on the National Fire Protection Association (NFPA) 472 Standard. The NFPA 472 Subcommittee will meet to discuss the future presentation to the NFPA 472 Technical Committee on Hazardous Materials Response Personnel about the initiative to draft a marine emergency responder chapter in NFPA 472, Professional Competence of Responders to Hazardous Materials Incidents. This meeting will be open to the public.

**DATES:** The teleconference call will take place on Tuesday, August 17, 2004, from 9:30 a.m. to 11:30 a.m. EDT. Written comments may be submitted on or before August 16, 2004.

ADDRESSES: Members of the public may participate by either calling in (see SUPPLEMENTARY INFORMATION) or by coming to Room 2100, U.S. Coast Guard Headquarters Building, 2100 Second Street, SW., Washington, DC 20593. We request that members of the public who plan to attend this meeting notify LT Matt Barker at 202 267–1217 so that he may notify building security officials. Written comments should be sent to CDR Robert J. Hennessy, Executive Director, CTAC, Commandant (G-MSO-3), 2100 Second Street, SW., Washington DC 20593-0001 or Fax: 202 267–4570. This notice is available on the Internet at *http://dms.dot.gov*.

# FOR FURTHER INFORMATION CONTACT:

Commander Robert J. Hennessy, Executive Director of CTAC, telephone 202 267–1217, fax 202 267–4570. **SUPPLEMENTARY INFORMATION:** Members of the public may participate by dialing 202 366–3920, Pass code: 1243. Public participation is welcomed; however, the number of teleconference lines is limited and are available on a first-come, first-served basis. Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. App. 2 (Pub. L. 92–463, 86 Stat. 770, as amended).

# Tentative Agenda

(1) Introduction of Subcommittee members and attendees.

- (2) Discussion on future Subcommittee presentation to the NFPA 472 Technical Committee on Hazardous Materials Response Personnel.
- (3) Public comment period.

#### **Public Participation**

The Chairman of this NFPA 472 Subcommittee shall conduct the teleconference in a way that will, in his judgment, facilitate the orderly conduct of business. During the teleconference, the Subcommittee welcomes public comment. Members of the public will be heard during the public comment period. The committee will make every effort to hear the views of all interested parties. Please note that the teleconference may close early if all business is finished. Written comments may be submitted on or before the day of the teleconference (*see* ADDRESSES).

#### Minutes

The teleconference will be recorded, and a summary will be available for public review and copying in the docket approximately 30 days following the teleconference meeting.

Dated: July 28, 2004.

### Joseph J. Angelo,

Director of Standards, Marine Safety, Security and Environmental Protection. [FR Doc. 04–17684 Filed 8–3–04; 8:45 am] BILLING CODE 4910–15–P

## DEPARTMENT OF HOMELAND SECURITY

#### **Coast Guard**

[CGD07-04-095]

# Reorganization of Group Key West and Marine Safety Detachment Marathon; Implementation of Sector Key West

**AGENCY:** Coast Guard, DHS. **ACTION:** Notice of organizational change. **SUMMARY:** The Coast Guard announces the consolidation of Group Key West and Marine Safety Detachment (MSD) Marathon into one command, Sector Key West. The Sector Key West Commanding Officer will have the authority, responsibility and missions of a Group Commander and Commanding Officer, Marine Safety Office (MSO). The Coast Guard has established a continuity of operations whereby all previous practices and procedures will remain in effect until superseded by an authorized Coast Guard official and/or document.

**DATES:** This notice is effective August 4, 2004.

**ADDRESSES:** Documents indicated in this preamble as being available in the docket are part of docket CGD07–04–095 and are available for inspection or copying at District 7 Resources, 9th Floor, 909 SE 1st Avenue, Miami, FL 33131 between 7:30 a.m. and 4:30 p.m., Monday through Friday, except Federal Holidays.

# FOR FURTHER INFORMATION CONTACT:

Lieutenant Carlos A. Cuesta, District 7 Resources Program at 305–415–6706.

## SUPPLEMENTARY INFORMATION:

#### **Discussion of Notice**

Sector Key West will be composed of a Response Department, Prevention Department, and Logistics Department. The Response and Logistics Departments will be located at Key West. The Prevention Department will be located at 1600 Overseas Highway, Marathon FL 33050. All existing missions and functions performed by Group Key West and MSD Marathon will be realigned under this new organizational structure as of August 5, 2004, and Group Key West and MSD Marathon will no longer exist as organizational entities.

Sector Key West will be responsible for all Coast Guard missions in the following zone: "the boundary of the Key West Marine Inspection Zone and Captain of the Port zone starts at a line bearing 111° T from the shoreline at 25° 25' N. Latitude, 80° 20' W. Longitude seaward to the extent of the economic exclusive zone; including all of Monroe County, Florida, then from the economic exclusive zone easterly along a line bearing 065° T to the coast at the Monroe and Collier County boundary." The following chart depicts this area. BILLING CODE 4910-15-P